Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Business / Lophos Holdings Inc. Corporate Update
Business corporate update

Lophos Holdings Inc. Corporate Update

Analysis based on 6 articles · First reported Jun 12, 2026 · Last updated Jun 12, 2026

Sentiment
-20
Attention
2
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The corporate update from Lophos Holdings Inc. indicates significant operational and regulatory challenges, including the loss of its Controlled Substances Dealer's Licence and a halted stock on the Canadian Securities Exchange. This news is likely to have a negative impact on investor confidence in Lophos Holdings Inc. and its future prospects, as the company faces an uphill battle to restore its regulatory standing and resume operations.

bioscience pharmaceuticals
Event Summary

Lophos Holdings Inc. provided a corporate update on June 11, 2026, detailing significant changes and challenges. Josh Herman was appointed CEO, and Cotton and Cory Harris joined the Board of Directors, with Evan Stawnyczy stepping down. The company also reconstituted its Audit Committee. A major setback is the loss of Lophos Pharmaceuticals Corporation's Controlled Substances Dealer's Licence (CSDL) due to the disposition of its licensed facility. This means Lophos Holdings Inc. no longer holds a CSDL and is actively evaluating strategic alternatives for future controlled substance activities. Furthermore, the company's securities remain subject to a failure-to-file cease trade order issued by the Canada — British Columbia Securities Commission on September 5, 2024, resulting in halted trading on the Canadian Securities Exchange. Management is prioritizing the completion of outstanding disclosure requirements to revoke the cease trade order and is focused on rebuilding its operational and regulatory foundation.

Key Actions
95 Lophos Pharmaceuticals Corporation lost CSDL
90 Lophos Holdings Inc. provided corporate update
90 Canada — British Columbia Securities Commission issued cease trade order Lophos Holdings Inc.
85 Canadian Securities Exchange halted trading Lophos Holdings Inc.
80 Josh Herman appointed CEO Lophos Holdings Inc.
70 Cotton appointed to Board Lophos Holdings Inc.
70 Cory Harris appointed to Board Lophos Holdings Inc.
60 Lophos Holdings Inc. reconstituted Audit Committee
40 Evan Stawnyczy stepped down Lophos Holdings Inc.
Entities Involved
priv
Lophos Holdings Inc.
Lophos Holdings Inc. provided a corporate update detailing leadership changes, the loss of its Controlled Substances Dealer's Licence, ongoing efforts to address a cease trade order, and its strategic outlook. The company is facing significant operational and regulatory challenges, including a halted stock and the need to rebuild its foundation.
Importance 100 Sentiment -30
priv
Lophos Pharmaceuticals Corporation
Lophos Pharmaceuticals Corporation, a wholly owned subsidiary of Lophos Holdings Inc., lost its site-specific Controlled Substances Dealer's Licence following the disposition of its facility.
Importance 80 Sentiment -40
per
Josh Herman
Josh Herman was appointed Chief Executive Officer and joined the Board of Directors of Lophos Holdings Inc., leading the company's restructuring efforts and strategic development.
Importance 70 Sentiment 10
govactor
Canada — British Columbia Securities Commission
The Canada — British Columbia Securities Commission issued a failure-to-file cease trade order against Lophos Holdings Inc., halting trading in its securities.
Importance 60 Sentiment 0
cmdt
Cotton
Cotton was appointed to the Board of Directors of Lophos Holdings Inc. and became Chair of the reconstituted Audit Committee, contributing to governance reorganization.
Importance 50 Sentiment 10
per
Cory Harris
Cory Harris was appointed to the Board of Directors of Lophos Holdings Inc. and joined the reconstituted Audit Committee, supporting the company's governance and restructuring.
Importance 50 Sentiment 10
exch
Canadian Securities Exchange
The Canadian Securities Exchange has halted trading in Lophos Holdings Inc.'s securities due to a cease trade order, pending revocation and exchange determination.
Importance 50 Sentiment 0
govactor
Canada — Health Canada
Canada — Health Canada is the issuer of the Controlled Substances Dealer's Licence that Lophos Pharmaceuticals Corporation previously held, impacting the company's ability to conduct controlled substance activities.
Importance 40 Sentiment 0
per
Claire Stawnyczy
Claire Stawnyczy, founder of Lophos Holdings Inc., continues to serve on the Board and supports the company's strategic development.
Importance 30 Sentiment 0
per
Evan Stawnyczy
Evan Stawnyczy stepped down from the Board of Directors of Lophos Holdings Inc. as part of the company's governance reorganization.
Importance 20 Sentiment -10
cnt
Canada
Canada is the country where Lophos Holdings Inc. operates and where its regulatory bodies, Canada — Health Canada and the Canada — British Columbia Securities Commission, are located.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.